Evidence map›Paper›PMID 42006742›Full record

ArticleBreast cancer (Dove Medical Press)2026

Single-Cell Profiling Reveals a Treg-Rich, NK Cell-Depleted Immune Microenvironment in Triple-Negative Breast Cancer with High-Glucocorticoid Receptor Expression.

Joshua Behar, Christine Shiang, Deniz Nesli Dolcen, Lynda B Bennett, Andrew W DeVilbiss, Margarite D Matossian, Isaac S Chan, Rita Nanda, Suzanne D Conzen, John T Lafin

Abstract read
In one paragraph

Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joshua Behar *Department of Internal Medicine, Division of Hematology & Oncology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.ORCID 0000-0003-4262-6434
Christine Shiang *Department of Internal Medicine, Division of Hematology & Oncology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Deniz Nesli DolcenDepartment of Internal Medicine, Division of Hematology & Oncology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Lynda B BennettDepartment of Internal Medicine, Division of Hematology & Oncology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Andrew W DeVilbissDepartment of Internal Medicine, Division of Hematology & Oncology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Margarite D MatossianDepartment of Medicine, Section of Hematology and Oncology, The University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, 60805, USA.
Isaac S ChanDepartment of Internal Medicine, Division of Hematology & Oncology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Rita NandaDepartment of Medicine, Section of Hematology and Oncology, The University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, 60805, USA.ORCID 0000-0001-5248-0876
Suzanne D ConzenDepartment of Internal Medicine, Division of Hematology & Oncology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
John T LafinDepartment of Urology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.

Funding

BASIC RESEARCH TRAINING IN MEDICAL ONCOLOGYT32CA009566 · NCI · UNIVERSITY OF CHICAGO · PI OLUFUNMILAYO F. OLOPADE · 1987 to 2026
$10.5M
NCI NIH HHS T32 CA009566
6 · The paper itself

Abstract

Purpose: Analyses of patients with early-stage, treatment-naïve triple-negative breast cancer (TNBC) have demonstrated that high glucocorticoid receptor (GR) expression in primary tumors is associated with poor prognosis. We previously observed that GR-high primary TNBCs exhibited significantly increased numbers of tumor-infiltrating regulatory T cells (Tregs) compared with GR-low tumors. To further investigate GR-associated immunologic features, we leveraged imaging mass cytometry (IMC) to profile additional immune cell phenotypes and spatial architecture in GR-high versus GR-low primary TNBC. Patients and Methods: Tumor-infiltrating immune cells were profiled in formalin-fixed paraffin-embedded (FFPE) core biopsies from five untreated GR-high and four GR-low TNBC tumors using IMC with a 21-antibody panel. Regions of interest (ROI) were selected within pan-cytokeratin-positive tumor nests. Data underwent unsupervised clustering, and cell types were identified based on protein expression profiles. Analyses compared cell-type abundance and spatial interactions in GR-high versus GR-low tumors. Results: GR-high tumors exhibited significantly greater Treg infiltration within tumor nests than GR-low tumors. GR-high TNBC also showed a comparatively greater abundance of activated memory CD8+ T cells, cytotoxic CD4+ T cells, and effector memory CD4+ T cells. In contrast, GR-low tumors exhibited relatively greater representation of HLA-ABC-positive (HLA-ABC+) cancer cells as well as early-activated dendritic cells (DCs) and natural killer (NK) cells. Spatial analysis revealed that Tregs in GR-high tumors colocalized more frequently with proliferating tumor cells relative to Tregs in GR-low tumors. NK cells in GR-high tumors displayed relatively less colocalization with proliferating tumor cells. Conclusion: Compared with GR-low disease, treatment-naïve GR-high primary TNBC exhibits a more immunosuppressive tumor microenvironment characterized by greater Treg density, closer Treg-cancer cell proximity, reduced NK cell infiltration, impaired immune surveillance, and decreased abundance of HLA-ABC+ cancer cells. These findings implicate TNBC cell GR signaling as immunosuppressive, likely through mechanisms resulting in both differential immune cell enrichment and altered spatial organization.

Indexed as

antigen presentationantitumor immunityimaging mass cytometrytissue architecturetumor infiltrating immune lymphocytes

Identifiers

PMID42006742
PMCPMC13091597

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.